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We thank Drs. Milanowski, Grassle and Uitti for their in-
terest in our article [1]. We agree that it is important to report 
every new patient who requires radiation therapy (RT) with 
implanted deep brain stimulation (DBS). As the number of 
DBS patients with concomitant cancer continues to rise, the 
influence of RT on those patients should be analysed. 
At the time of qualification for DBS, both of our patients 
had cancer histories: the first patient had been diagnosed 
with prostate cancer and was undergoing hormone therapy, 
stable on urological examination and biochemical markers; 
the second patient had a history of left-sided mastectomy 
due to breast cancer. Such patients may be considered as 
being at risk if they were to encounter future RT. Important 
factors determining the risk of harmful interference from RT 
to DBS include the incidence of specific cancer type and its 
localisation. The reported DBS patient with non-Hodgkin’s 
lymphoma affecting the lymph node in the vicinity of the 
internal pulse generator (IPG) represents an important clini-
cal dilemma [2]. This neoplasm is listed by the American 
Cancer Society as being one of the most common cancers 
in the United States, and RT is a viable treatment option [3]. 
Other common cancers that may interfere with the DBS sys-
tem, especially with pulse generators that are usually placed 
in the infraclavicular region, include lung and breast cancer. 
The latter was the culprit in our second patient, in whom RT 
of the left subclavian area with 15 MV photons and a dose of 
20 Gy in five fractions was carried out (Fig. 1). The maximal 
estimated radiation dose for left IPG was 1.7 Gy. In a case 
report by Brokenhagen et al., the maximal radiation dose for 
IPG was over 48 Gy. 
Broader experience with pacemakers and implantable car-
dioverter defibrillators (PM/ICD) has shown that the impact 
of RT on a device depends on the beam energy rather than 
on the total dose of radiation [4]. In the two aforementioned 
cases, the maximal recommended beam energy (< 10MV) 
and maximal recommended radiation dose were far exceeded, 
but fortunately no complications from IPG were observed. 
The surgical relocation of IPG is an option for minimising its 
exposure for RT [5], but possible malignant DBS withdrawal 
syndrome associated with acute cessation or failure of the 
DBS device must be considered [6]. In addition, maintaining 
neurostimulation during an RT procedure is crucial to avoid 
unwanted involuntary movements such as the head tremor in 
the case reported by Mazdai et al. [7]. 
In summary, despite the lack of structured studies, RT has 
been safely delivered in all patients with DBS reported thus far. 
Nonetheless, further multidisciplinary efforts should be made 
so as to ascertain the safety and feasibility of radiotherapy in 
patients with implanted DBS.
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